Numerous staging and scoring systems exist for differentiated thyroid cancer (DTC), but all harbor limitations. This has prompted investigation for new factors with prognostic implications for DTC.
INTRODUCTION
Thyroid cancer is now the eighth most common cancer in the United States, and its incidence is rising [1] [2] [3] [4] . Data from the Surveillance, Epidemiology and End Results Program (SEER) predict that an estimated 60 220 men and women will be diagnosed with thyroid cancer, and 1850 men and women will die of thyroid cancer in 2013 [5] . Differentiated thyroid cancer (DTC) represents more than 90% of all thyroid cancers and carries the best prognosis with a 10-year survival rate greater than 90% [6] .
Several risk stratification systems for thyroid cancer have been proposed based on the likelihood of disease-specific death after initial diagnosis. The American Joint Committee on Cancer (AJCC) tumor, lymph nodes, metastasis (TNM) staging system is the most commonly used system and is based on an age cutoff of 45 years of age. Several scoring systems have also been developed including the Metastases, Age, Completeness of resection, Invasion and Size (MACIS) score and Age, Metastases, Extent of disease and Size (AMES), whose predictive values are limited to papillary thyroid cancer [7] [8] [9] [10] [11] [12] [13] [14] [15] . All staging and scoring systems have the characteristic that with advancing stage, all-cause and cancerspecific mortality rises [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
Despite accepted existing risk stratification systems, several limitations exist. These systems address survival rates and not recurrence, and as the number of deaths from thyroid cancer is small, this poses a restriction in the use of the current risk stratification systems. Moreover, a small risk of death or recurrence still exists in patients with DTC classified as low risk, thus necessitating longterm follow-up. This has led to the creation of new risk stratification systems estimating recurrence of thyroid cancer [18] [19] [20] [21] . However, in terms of survival, new predictive factors for continuous risk assessment are also needed and are currently being investigated.
The purpose of this review is to present recent updates in the literature on new potential risk stratification predictors for DTC. For the purpose of this article, we will focus on survival, not recurrence.
NEW POTENTIAL FACTORS INVOLVED IN DIFFERENTIATED THYROID CANCER RISK STRATIFICATION
Several potential factors that may be involved in DTC risk stratification have recently been investigated and are described below, including age, sex, lymph node involvement, thyroid stimulating hormone (TSH) and molecular markers ( Table 1 ).
Age
DTC is the only human malignancy to include age as part of the staging system, despite the fact that advanced age is known to be associated with worse survival in many types of cancer [22, 23] . Traditionally, the age cutoff of 45 years has been and continues to be used in current DTC staging guidelines [24] . However, new research has recently emerged evaluating the impact of age on DTC survival.
A retrospective analysis based on the SEER database examined patients diagnosed with either papillary or follicular thyroid cancer between 1988 and 2003 (n ¼ 29 225), and conducted Kaplan-Maier survival analyses to estimate disease-specific survival based on patient age range. The study showed that patients aged 45 years and older had significantly worse survival than younger patients (P <0.0001). More specifically, there was a significant decrease in disease-specific survival first seen in patients aged 35 years and older and survival continued to steadily decrease with each additional decade of age (P <0.001). The study concluded that increasing age is associated with poorer survival in DTC, and this relationship represents a continuum [25] .
Also using the SEER database, Bischoff et al. [26 && ] obtained data for histology-confirmed papillary thyroid cancer and stratified them in 5-year categories by age at diagnosis from 20 to 64 years old, with patients 65 years of age and older categorized together (n ¼ 53 581). Overall 5-year survival remained above 90% for all age groups under 65 years, whereas patients who are 65 years old and over had a progressively less favorable prognosis with each advancing age group.
In another study, Amphlett et al. [27] identified thyroid cancer cases registered in the Welsh Cancer Intelligence and Surveillance Unit from 1985 through 2010 (n ¼ 1747) and performed survival analyses. Survival was determined for 5-year diagnosis periods for all-cause mortality and thyroid cancer-specific mortality. Factors that significantly
KEY POINTS
Many staging and scoring systems for DTC currently exist, but limitations have prompted investigation for new prognostic markers in risk stratification.
The current age cutoff of 45 years in existing DTC staging guidelines is being challenged, and new data are emerging that an older age cutoff or evaluating age as a continuum may be more appropriate prognostically.
The influence of sex on DTC survival is controversial, and further studies are needed to determine its significance.
Further research is needed to delineate the effect of lymph node involvement on DTC survival and the role of prophylactic central lymph node dissection in these patients.
New potential risk stratifiers for DTC are emerging, including TSH and molecular markers, such as BRAF, RAS, RET/PTC and PAX8/PPARg. reduced survival included age over 65 years (P <0.001, >65 versus 15-64 years), as well as male sex. Survival data were also collected in a prospective database study conducted on 2011 DTC patients at a single German hospital from 1980 to 2011. Survival data for the general German population were obtained and matched to the DTC population studied for age and sex. The authors demonstrated that patients who were at least 45 years old at diagnosis and had extensive perithyroidal invasion (AJCC/TNM stages IVa and IVb), lateral cervical lymph node metastases (stage IVa) or distant metastases (stage IVc) showed a clearly reduced life expectancy. In patients who were over 60 years of age at diagnosis, the loss of life expectancy was greater than for those aged 45-59 years in all groups. The life expectancy was not reduced in patients with TNM stages I, II or III [16] .
New data are emerging on the prognostic significance of age in DTC that suggest an older age than 45 may be a more accurate age cutoff for prognosis. The use of an older age cutoff would lead to downstaging many patients with DTC, and may lead to potentially avoiding unnecessary ancillary therapies in patients with favorable prognosis. Further studies are required to determine whether an older age cutoff versus a staging system using age as a continuum is needed.
Sex
Despite a higher incidence of DTC, overall survival was reported to be better in women in several cohorts both by univariate and multivariate analyses [28] [29] [30] [31] . It is hypothesized that worse outcomes in men may potentially be accounted for by a more aggressive behavior of DTC in these patients. Other studies have shown no effect of sex on overall survival [32, 33] .
A recent study by Jonklaas et al. [34 && ] aimed to determine whether there were sex differences in the overall and disease-specific mortality of patients with papillary thyroid cancer in the National Thyroid Cancer Treatment Cooperative Study Group Registry (n ¼ 3 572). The study concluded that a sex advantage in survival for women with papillary thyroid cancer reflected a generalized sex advantage seen in the US population. They also showed that once the diagnosis of papillary thyroid cancer was made, disease-specific survival of women was similar to men after adjusting for presenting disease stage and age. In addition, although with adjustments for stage women as a group had a similar disease-specific survival to men, women with stage I and II disease had better outcomes than men when comparing individuals diagnosed before the age 55 years old.
The impact of the age cutoff of 55 years is interesting as this corresponds to the age at which most women in the United States have attained menopause [35, 36] .
Yang et al. [37] studied patients registered in the SEER database with thyroid cancer (n ¼ 29 225) and found that male patients showed higher cumulative incidence of death compared with their female counterparts (P <0.001). Nilubol et al. [38] also used the SEER database and performed multivariate analyses between male sex, disease-specific survival and features of tumor aggressiveness in thyroid cancer of follicular cell origin (n ¼ 61 523). They found that sex was not an independent prognostic factor for disease-specific survival.
Another recent study investigated the correlation between sex and the thyroid cancer mortality in a cohort of 435 patients who underwent thyroid surgery for stage II-IV papillary thyroid cancer [39 & ]. They demonstrated that 20.6% of women as compared to 40.8% of men exhibited postoperative disease progression. Multiple regression analysis showed that male sex was an independent risk factor for thyroid cancer recurrence and mortality.
The influence of sex on DTC survival is controversial, as sex-related ascertainment bias may exist. It is possible that men reach medical attention at an older age with more advanced disease, or women present earlier and are screened more thoroughly. Also, as women have lower all-cause mortality rates and live longer than men [40] , mortality should be adjusted to sex-specific overall survival rates. Moreover, literature that has examined the impact of estrogen on thyroid cancer is inconsistent, and numerous studies have reported conflicting relationships between estrogen status and incidence and aggressiveness of DTC [41] [42] [43] [44] [45] [46] [47] . Recently, published guidelines concerning high-risk cases of papillary and follicular thyroid carcinomas do not consider sex as a risk factor [24] , and further research is needed to determine whether there is a correlation.
Lymph node involvement
DTC staging systems consider metastatic lymph nodes, when included, as a binary entity that is presence versus absence. The extent of initial surgery and the role of lymph node dissection for papillary thyroid cancer remain controversial. The debate stems from the uncertain prognostic significance of metastatic cervical lymph nodes in papillary thyroid cancer, as with thorough inspection up to 90% of patients will have micrometastatic disease [48, 49] . The association between clinically positive lymph node metastases and recurrence is well recognized [50] , but their significance on survival remains debatable.
The impact of lymph node involvement in survival in patients with papillary and follicular thyroid cancer was investigated in a study of 33 088 patients identified in the SEER registry between 1988 and 2003 [51] . Patients were stratified by age (<45 versus 45 years) and disease (papillary/follicular). It was established that in patients with papillary thyroid cancer below 45 years, lymph node disease did not influence survival (P ¼ 0.535), whereas in patients of at least 45 years, lymph node involvement was associated with 46% increased risk of death (P < 0.001). In patients with follicular carcinoma lymph node involvement conferred increased risk of death in both age groups (P 0.002).
By utilizing the SEER database, Schneider et al. [52 && ] analyzed adult patients who underwent thyroidectomy with lymph node dissection (n ¼ 10 955), and a lymph node ratio (metastatic lymph nodes to total lymph nodes) was calculated. Patients with less than three lymph nodes collected were excluded. After comparing Kaplan-Meier survival estimates and overall disease-specific mortality rates, they found that patients with a lymph node ratio of at least 0.42 experienced a 77% higher disease-specific mortality rate compared with those with metastatic lymph nodes as a whole.
Beal et al. [53] also used the SEER database to identify all patients with primary nonmetastatic DTC who underwent thyroidectomy with at least one lymph node removed between 1988 and 2004. Kaplan-Meier survival curves for lymph node yield (number of lymph nodes harvested) and metastatic lymph node ratio were compared. In multivariable analysis, increasing lymph node yield was associated with poorer survival in all patients (P ¼ 0.001) and node-negative patients (P ¼ 0.03), but not for nodepositive patients (P ¼ 0.27). Metastatic lymph node ratio did not influence survival in node-positive patients (P ¼ 0.84).
More recently, another study determined that the lymph node ratio is an important independent prognostic factor in papillary thyroid cancer and can be used in conjunction with the existing staging systems [54 & ]. A retrospective analysis was conducted of 198 patients with papillary thyroid cancer undergoing total thyroidectomy with neck dissection at a single institution between 1987 and 2011. The lymph node ratio was associated with a decrease in disease-free survival (P ¼ 0.005). Patients with a lymph node ratio of 0.30 or higher had a 3.4 times higher risk of persistent or recurrent disease compared with patients with a lymph node ratio of 0 (P ¼ 0.031).
There is an ongoing controversy regarding the association of lymph node involvement in DTC and survival, and whether prophylactic central lymph node dissection should be performed in these patients. Randomized prospective controlled trials are currently lacking, and more research is needed to determine the prognostic role of prophylactic central lymph node dissection in the management of DTC.
Thyroid stimulating hormone
Serum TSH concentration is directly associated with the risk of cancer in a thyroid nodule [55] [56] [57] , and TSH suppression has been shown to improve prognosis of high-risk DTC patients [58] [59] [60] . In a retrospective cohort study of 1198 patients who underwent thyroid surgery at a single hospital for DTC, risk of malignancy correlated with higher TSH level on both univariate and multivariate analyses (P ¼ 0.007) [57] . More specifically, the likelihood of malignancy was 16% when serum TSH was less than 0.06 mIU/l versus 52% when 5 mIU/l or greater (P ¼ 0.001). In another retrospective cohort study by the same investigators, mean TSH was shown to be significantly higher in thyroid cancer patients regardless of age [61] .
Serum TSH has also been associated not only with thyroid cancer incidence but also with advanced tumor stage [56, 57, 62] . A recent systematic review by and Vitti et al. [56] examined studies focusing on the relationship between TSH and DTC. It was concluded that in patients with nodular thyroid disease, the risk of thyroid malignancy increases with serum TSH, and even within normal ranges, higher TSH values are associated with a higher frequency and more advanced stage of thyroid cancer. Haymart et al. [61] also showed that higher serum TSH level is associated with extrathyroidal extension of disease in a retrospective cohort study of 1361 patients who underwent thyroid surgery between 1994 and 2007 at a single institution. On multivariate analysis of high-risk features associated with poor prognosis, there was a significant association between higher TSH and extrathyroidal extension (P ¼ 0.002). Another study also evaluated the association of preoperative serum TSH levels with the advance of DTC and its highrisk clinicopathological features in Korean patients. Using multiple logistic regression, they found that preoperative TSH level was a predictive factor for the presence of extrathyroidal extension (P ¼ 0.008) and lateral lymph node metastases (P ¼ 0.025) [62] .
In order to assess the prognostic significance of serum TSH and thyroglobulin antibody status at the time of patients' thyroid cancer diagnosis, McLeod et al. [63] analyzed prospective data from The National Thyroid Cancer Treatment Cooperative Study, a large nonrandomized thyroid cancer registry. Geometric mean serum TSH levels were higher in patients with higher stage disease (stage III/IV ¼ 1.48 versus 1.02 mIU/l for stages I/II; P ¼ 0.006), and this relationship persisted in those aged 45 years or older after adjusting for sex (P ¼ 0.01). Disease recurrence and all-cause mortality occurred in 37 and 38 TSH cohort patients respectively, which limited the power for survival analysis in this study. Perioperative thyroglobulin antibody titer was not an independent predictor of DTC prognosis. Of note, a positive serum thyroglobulin antibody test was deemed an independent predictor for thyroid malignancy in a thyroid nodule, regardless of the presence of autoimmune thyroiditis, in another study [64] .
Molecular markers
Substantial developments have occurred in understanding the molecular mechanisms of thyroid cancer in the past 5-10 years [65] . Several molecular markers have been studied for their diagnostic and prognostic significance on the basis of which more effective management strategies for DTC are being developed.
Numerous studies have shown that BRAF mutation is a prognostic genetic marker that has improved risk stratification and has tailored management of patients with thyroid cancer, including those with conventionally low-risk disease. BRAF mutation is highly prevalent in recurrent papillary thyroid cancer, ranging from 78 to 95% [66] [67] [68] [69] . As the disease-specific survival among patients with papillary thyroid cancer is excellent, BRAF mutational status may be most relevant to recurrence risk. The addition of BRAF mutational status to established risk algorithms has been shown to improve the discrimination of risk recurrence in patients undergoing total thyroidectomy for papillary thyroid cancer. The 5-year cumulative papillary thyroid cancer recurrence incidence in a 356 patient cohort was 20% among patients with BRAF V600E versus 8% of patients with BRAF wild type. BRAF V600E was significantly associated with time to recurrence when added to the AMES, MACIS, AJCC/TNM and American Thyroid Association recurrence-risk category [70] .
Many large well designed studies demonstrated a close association of BRAF mutation with major clinicopathological risk factors, such as extrathyroidal extension, lymph node metastasis and advanced TNM stage III/VI of papillary thyroid cancer, which are associated with increased rates of recurrence and mortality [71] . In a retrospective review of 977 papillary thyroid microcarcinoma cases that underwent surgical resection between 2001 and 2010 at a single institution, univariate analysis showed that BRAF V600E mutation was significantly associated with advanced disease stage. Multiple logistic regression analyses showed a significant association between BRAF V600E and extrathyroidal extension and lymph node metastases [72] .
In another retrospective study of 1849 patients with papillary thyroid cancer who underwent initial treatment at 13 centers in seven countries between 1978 and 2011, the presence of BRAF V600E mutation was significantly associated with increased cancerrelated mortality. Overall mortality was 5.3% in BRAF V600E positive versus 1.1% in mutationnegative patients (P < 0.001) [73 && ]. On the contrary, Zoghlami et al. [74] conducted a retrospective study in which BRAF mutation status did not significantly correlate with various clinicopathological factors studied including advanced age, extrathyroidal extension, multifocal tumor, cervical lymph node metastasis, tumor size and advance stage. The same study showed no significant difference in tumor recurrence rate between the two subgroups of mutant BRAF and wild-type BRAF patients.
In contrast to BRAF mutation, RAS mutations and RET/PTC rearrangements, which are also common genetic alterations in papillary thyroid cancer, are much less commonly associated with aggressive pathogenesis [75] . The significance of RAS mutations was examined in a large number of follicular thyroid adenomas and carcinomas at a single institution in Japan [76] . It was found that 30% of adenomas versus 57% of carcinomas harbored RAS mutations, which was predominantly found in the NRAS codon 61 (P <0.01), and the rate of gene mutations was significantly higher in the carcinomas than the adenomas (P <0.01). The NRAS codon 61 mutation in follicular carcinomas was positively associated with distant metastases (P <0.05), and RAS mutations were associated with poor overall patient survival (P <0.05). RAS mutations were also studied by Gupta et al. [77] by looking at 68 aspirates from 66 patients undergoing fine-needle aspiration. All RAS-positive papillary thyroid cancers (n ¼ 46) were found to be of low-grade follicular variant histology.
Mutational analysis was performed on 62 papillary thyroid cancers in regions surrounding Chernobyl, Ukraine, to assess the associations between mutation types and thyroid cancer risk [78] . RET/PTC rearrangements were most common (35%), followed by BRAF (15%) and RAS (8%) point mutations. Two tumors were identified that carried PAX8/PPARg. There was an association found between chromosomal rearrangements, but not point mutations, and I-131 exposure, pointing to a possible role of iodine deficiency in generation of RET/PTC rearrangements in these patients [78] . A study investigating follicular Hurthle cell tumors found that RET/PTC rearrangements existed in 38% of follicular Hurthle cell carcinomas, and PAX8/PPARg rearrangement was present in 27% [79] .
CONCLUSION
A number of staging and scoring systems exist for DTC, but these harbor limitations. This has elicited further investigation for new factors with potential prognostic implications for DTC, including TSH and molecular markers, and led to challenging of current controversial prognostic markers, such as age, sex and lymph node involvement. Further research is needed to delineate the role of these markers in DTC prognosis and whether their inclusion in staging is warranted.
